Tirzepatide, the Strongest Weight Loss Drug -By Polypeptide.ltd
Authoritative source：PubChem
Tirzepatide vs. Semaglutide Tirzepatide and semaglutide are both medications used for the treatment of type 2 diabetes, but they differ in several aspects: ❶ Mechanism of Action. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. On the other hand, semaglutide is a GLP-1 receptor agonist, which means it selectively activates the GLP-1 receptor.
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
❷ Dosage Frequency. Tirzepatide is administered once weekly, while semaglutide is available in different formulations with varying dosing frequencies, including once-daily and once-weekly options. ❸ Efficacy. Clinical trials have shown that both tirzepatide and semaglutide can effectively lower blood sugar levels and improve glycemic control in individuals with type 2 diabetes. Additionally, both medications have demonstrated potential for weight loss as an additional benefit. ❹ Weight Loss Effects. Both tirzepatide and semaglutide have shown efficacy in promoting weight loss in clinical trials. However, it's important to note that as of my knowledge cutoff in September 2021, semaglutide has received FDA approval as a weight loss medication in a higher-dose formulation specifically for chronic weight management, while tirzepatide had not yet received such approval. ❺ Side Effects. The side effects of tirzepatide and semaglutide can be similar and may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. However, the specific side effects and their incidence can vary between individuals and should be discussed with a healthcare professional. ❻ FDA Approval. As of my knowledge cutoff in September 2021, both tirzepatide and semaglutide have received FDA approval for the treatment of type 2 diabetes. Semaglutide has also received FDA approval for chronic weight management in a higher-dose formulation.
Reference citations [1] Ahangarpour M, Kavianinia I, Harris PW, Brimble MA (January 2021). "Photo-induced radical thiol-ene chemistry: a versatile toolbox for peptide-based drug design". Chemical Society Reviews. Royal Society of Chemistry. 50 (2): 898–944. doi:10.1039/d0cs00354a. PMID 33404559. S2CID 230783854. [2] "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain. [3] Jump up to:a b c d e f g h i j k l "Drug Trials Snapshots: Mounjaro". U.S. Food and Drug
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
Administration (FDA). 13 June 2023. Retrieved 14 June 2023. this source, which is in the public domain.
This article incorporates text from
[4] Dutta D, Surana V, Singla R, Aggarwal S, Sharma M (November–December 2021). "Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis". Indian Journal of Endocrinology and Metabolism. 25 (6): 475–489. doi:10.4103/ijem.ijem_423_21. PMC 8959203. PMID 35355921. [5] Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. (4 June 2022). "Tirzepatide Once Weekly for the Treatment of Obesity". NEJM. 387 (3): 205–216. doi:10.1056/NEJMoa2206038. PMID 35658024. S2CID 249385412. Archived from the original on 5 June 2022. Retrieved 6 June 2022. [6] "Lilly : Phase 3 Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes". Business Insider. RTTNews. 19 October 2021. Archived from the original on 28 October 2021. Retrieved 28 October 2021. [7] Kellaher, Colin (28 April 2022). "Eli Lilly's Tirzepatide Meets Main Endpoints in Phase 3 Obesity Study". MarketWatch. Dow Jones Newswires. Archived from the original on 29 April 2022. Retrieved 29 April 2022. [8] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. (August 2021). "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes". The New England Journal of Medicine. 385 (6): 503–515. doi:10.1056/NEJMoa2107519. PMID 34170647. S2CID 235635529. [9] Dee, Jane E. (6 June 2022). "More Than 20% Weight Reduction in Individuals With Obesity". Yale Department of Internal Medicine. Archived from the original on 10 June 2022. Retrieved 12 June 2022. [10] Davis, Nicola (5 June 2022). "Diabetes drug leads to notable weight loss in people with obesity – study". The Guardian. Archived from the original on 11 June 2022. Retrieved 12 June 2022. [11] World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896. [12] Jump up to:a b c "Mounjaro EPAR". European Medicines Agency (EMA). 18 July 2022. Archived from the original on 12 December 2022. Retrieved 2 January 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
provided the source is acknowledged. [13] Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G (November 2022). "Tirzepatide: A Systematic Update". Int J Mol Sci. 23 (23). doi:10.3390/ijms232314631. PMC 9741068. PMID 36498958. [14] "Mounjaro: Pending EC decision". European Medicines Agency. 22 July 2022. Archived from the original on 28 July 2022. Retrieved 30 July 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. [15] "Mounjaro Product information". Union Register of medicinal products. Archived from the original on 8 February 2023. Retrieved 3 March 2023. [16] "Drug and Health Product Submissions Under Review (SUR): New drug submissions completed". Health Canada. 10 March 2021. Archived from the original on 5 January 2023. Retrieved 5 January 2023. [17] Jump up to:a b Min T, Bain SC (January 2021). "The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials". Diabetes Therapy. 12 (1): 143–157. doi:10.1007/s13300-020-00981-0. PMC 7843845. PMID 33325008.
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/